Endocyte, a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer, completed a $86.2 million shelf-takedown offering of more than 20 million shares of common stock, which included full exercise of the underwriters' greenshoe option. Our firm advised Endocyte in the offering.
The shares trade on the Nasdaq Global Market under the symbol "ECYT." Jefferies LLC, Wells Fargo Securities, LLC, and Deutsche Bank Securities Inc. acted as joint book-running managers for the offering. Wedbush Securities Inc. acted as co-lead manager for the offering.
